JP2017531033A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531033A5
JP2017531033A5 JP2017533726A JP2017533726A JP2017531033A5 JP 2017531033 A5 JP2017531033 A5 JP 2017531033A5 JP 2017533726 A JP2017533726 A JP 2017533726A JP 2017533726 A JP2017533726 A JP 2017533726A JP 2017531033 A5 JP2017531033 A5 JP 2017531033A5
Authority
JP
Japan
Prior art keywords
quinidine
item
dextromethorphan
salt
items
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017533726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531033A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049934 external-priority patent/WO2016040930A1/en
Publication of JP2017531033A publication Critical patent/JP2017531033A/ja
Publication of JP2017531033A5 publication Critical patent/JP2017531033A5/ja
Pending legal-status Critical Current

Links

JP2017533726A 2014-09-14 2015-09-14 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 Pending JP2017531033A (ja)

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US201462050170P 2014-09-14 2014-09-14
US62/050,170 2014-09-14
US201462061451P 2014-10-08 2014-10-08
US62/061,451 2014-10-08
US201462063122P 2014-10-13 2014-10-13
US62/063,122 2014-10-13
US201462063861P 2014-10-14 2014-10-14
US62/063,861 2014-10-14
US201462068742P 2014-10-26 2014-10-26
US62/068,742 2014-10-26
US201562111053P 2015-02-02 2015-02-02
US62/111,053 2015-02-02
US201562111590P 2015-02-03 2015-02-03
US62/111,590 2015-02-03
US201562128446P 2015-03-04 2015-03-04
US62/128,446 2015-03-04
US201562162140P 2015-05-15 2015-05-15
US62/162,140 2015-05-15
US201562165535P 2015-05-22 2015-05-22
US62/165,535 2015-05-22
US201562169997P 2015-06-02 2015-06-02
US62/169,997 2015-06-02
US201562180026P 2015-06-15 2015-06-15
US62/180,026 2015-06-15
US201562193347P 2015-07-16 2015-07-16
US62/193,347 2015-07-16
US201562205061P 2015-08-14 2015-08-14
US62/205,061 2015-08-14
US201562216636P 2015-09-10 2015-09-10
US62/216,636 2015-09-10
US201562217142P 2015-09-11 2015-09-11
US201562217470P 2015-09-11 2015-09-11
US62/217,142 2015-09-11
US62/217,470 2015-09-11
PCT/US2015/049934 WO2016040930A1 (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019201410A Division JP2020019818A (ja) 2014-09-14 2019-11-06 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物

Publications (2)

Publication Number Publication Date
JP2017531033A JP2017531033A (ja) 2017-10-19
JP2017531033A5 true JP2017531033A5 (cg-RX-API-DMAC7.html) 2017-11-30

Family

ID=55459653

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017533726A Pending JP2017531033A (ja) 2014-09-14 2015-09-14 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物
JP2019201410A Withdrawn JP2020019818A (ja) 2014-09-14 2019-11-06 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物
JP2021036318A Active JP7360409B2 (ja) 2014-09-14 2021-03-08 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物
JP2023096152A Pending JP2023105265A (ja) 2014-09-14 2023-06-12 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019201410A Withdrawn JP2020019818A (ja) 2014-09-14 2019-11-06 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物
JP2021036318A Active JP7360409B2 (ja) 2014-09-14 2021-03-08 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物
JP2023096152A Pending JP2023105265A (ja) 2014-09-14 2023-06-12 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物

Country Status (15)

Country Link
US (3) US20190111047A1 (cg-RX-API-DMAC7.html)
EP (4) EP3708168A3 (cg-RX-API-DMAC7.html)
JP (4) JP2017531033A (cg-RX-API-DMAC7.html)
KR (1) KR20170052684A (cg-RX-API-DMAC7.html)
CN (3) CN107072990A (cg-RX-API-DMAC7.html)
AU (3) AU2015314710A1 (cg-RX-API-DMAC7.html)
CA (1) CA2960031A1 (cg-RX-API-DMAC7.html)
IL (2) IL250786A0 (cg-RX-API-DMAC7.html)
MX (3) MX2017003066A (cg-RX-API-DMAC7.html)
MY (1) MY198587A (cg-RX-API-DMAC7.html)
PH (1) PH12017500444A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017112747A (cg-RX-API-DMAC7.html)
SG (2) SG10201901242PA (cg-RX-API-DMAC7.html)
TW (3) TWI869633B (cg-RX-API-DMAC7.html)
WO (1) WO2016040930A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792662B1 (en) 2007-05-01 2016-04-06 Concert Pharmaceuticals Inc. Morphinan compounds
US20180243289A1 (en) * 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
WO2017020014A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
ES2840078T3 (es) 2016-07-04 2021-07-06 Avanir Pharmaceuticals Inc Métodos para la síntesis de dextrometorfano deuterado
CN110831584B (zh) * 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
JP7582869B2 (ja) 2018-05-18 2024-11-13 アナベックス ライフ サイエンス コーポレイション レスポンダ選択および治療の最適化されたsigma-1アゴニスト方法
PT3908270T (pt) * 2019-01-07 2025-11-12 Antecip Bioventures Ii Llc Combinação de dextrometorfano e bupropiona para tratar depressão em doentes asiáticos
WO2020190971A1 (en) * 2019-03-18 2020-09-24 Avanir Pharmaceuticals, Inc. Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
AU2021263354A1 (en) * 2020-04-27 2022-10-27 Avanir Pharmaceuticals Inc. Methods of treating agitation associated with Alzheimer's disease
CN115245515A (zh) * 2021-04-27 2022-10-28 杭州剂泰医药科技有限责任公司 一种组合物的医药用途
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
CN113209042A (zh) * 2021-05-28 2021-08-06 珠海润都制药股份有限公司 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法
CA3236017A1 (en) * 2021-10-27 2023-05-04 Sanjay Dube Methods of treating agitation associated with alzheimer's disease
CN116459255A (zh) * 2022-01-19 2023-07-21 深圳信立泰药业股份有限公司 氘代右美沙芬与安非他酮联合在制备ad激越的药物中的用途
US11730706B1 (en) * 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
KR20250120917A (ko) 2024-02-02 2025-08-11 단국대학교 천안캠퍼스 산학협력단 덱스트로메토르판을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물
KR20250129211A (ko) 2024-02-22 2025-08-29 단국대학교 천안캠퍼스 산학협력단 데가렐릭스를 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학적 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
TW264473B (cg-RX-API-DMAC7.html) * 1993-01-06 1995-12-01 Hoffmann La Roche
US5863927A (en) 1994-09-22 1999-01-26 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
ES2352739T3 (es) 1997-11-21 2011-02-22 Purdue Neuroscience Company 2-aminoacetamidas sustituidas y el uso de las mismas.
IL137974A0 (en) 1998-03-26 2001-10-31 Shionogi & Co Indole derivatives having antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
MX2008009947A (es) * 2006-02-03 2008-10-20 Avanir Pharmaceuticals Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
EP2001534A4 (en) * 2006-03-07 2013-07-03 Univ Florida SYSTEM FOR MONITORING THE COMPLIANCE OF MEDICINAL DOSES
WO2008097924A2 (en) * 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
CA2685723C (en) * 2007-05-01 2013-06-18 Concert Pharmaceuticals Inc. Morphinan compounds
EP2792662B1 (en) * 2007-05-01 2016-04-06 Concert Pharmaceuticals Inc. Morphinan compounds
EA019343B1 (ru) * 2008-09-19 2014-02-28 Консерт Фармасьютикалз Инк. Дейтерированные морфинановые соединения
HUE028956T2 (en) * 2008-10-30 2017-01-30 Concert Pharmaceuticals Inc Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
EA201391720A1 (ru) * 2008-11-14 2014-04-30 Консерт Фармасьютикалс Инк. Замещенные диоксопиперидинилфталимидные производные
SG10201911808QA (en) * 2013-11-05 2020-01-30 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan

Similar Documents

Publication Publication Date Title
JP2017531033A5 (cg-RX-API-DMAC7.html)
CA2883751C (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
JP2019059760A5 (cg-RX-API-DMAC7.html)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2021080300A5 (cg-RX-API-DMAC7.html)
JP2015517488A5 (cg-RX-API-DMAC7.html)
JP2017506624A5 (cg-RX-API-DMAC7.html)
JP2014114295A5 (cg-RX-API-DMAC7.html)
JP2009525343A5 (cg-RX-API-DMAC7.html)
RU2013121788A (ru) Ингибиторы репликации вич
RU2017112747A (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
JP2012193216A5 (cg-RX-API-DMAC7.html)
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
JP2015528471A5 (cg-RX-API-DMAC7.html)
JP2015038135A5 (cg-RX-API-DMAC7.html)
JP2018529742A5 (cg-RX-API-DMAC7.html)
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2016539156A5 (cg-RX-API-DMAC7.html)
JP2018530578A5 (cg-RX-API-DMAC7.html)
JP2012523437A5 (cg-RX-API-DMAC7.html)
JP2018527305A5 (cg-RX-API-DMAC7.html)
JP2017533220A5 (cg-RX-API-DMAC7.html)
EP2796450A4 (en) 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
MX2023001014A (es) Composiciones farmaceuticas que comprenden venglustat.
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний